Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lefamulin NDA Filed in Mainland China for Treatment of Community Acquired Pneumonia
Details : Sumitomo filed NDA to market oral and IV formulations of lefamulin,first systemic pleuromutilin antibiotic for the treatment of community-acquired pneumonia in adults in mainland China.
Product Name : Xenleta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2021
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable